RxDoctor Payments Data

Hayley Entrekin

Primary Care · Birmingham, ALNPI 1619495348

Payments from drug & device makers

$1,063in general payments, 2019–2025

Across 10 payments — averaging $106.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$250
  • Teva Pharmaceuticals USA, Inc.$130
  • Eisai Inc.$121
  • Lilly USA, LLC$120
  • AbbVie$118
  • Corcept Therapeutics$99
  • plus $224 from 3 others

What the payments were for

  • Food & beverage$1,063100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,063 in reported general payments places this provider in the 55th percentile of 159 primary care providers in Alabama.

See all primary care providers in Alabama

Medicare billing

Part B allowed, 2024
$26,170
Medicare patients
220
Services billed
527

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban264$250,801
OzempicSemaglutide138$191,125
JardianceEmpagliflozin138$160,067
MounjaroTirzepatide71$79,585
XareltoRivaroxaban41$44,259
TrulicityDulaglutide35$44,058
Trelegy ElliptaFluticasone/Umeclidin/Vilanter30$23,403
JanuviaSitagliptin Phosphate25$20,366
RybelsusSemaglutide13$19,525
Breo ElliptaFluticasone/Vilanterol30$17,983
FarxigaDapagliflozin Propanediol17$17,306
EntrestoSacubitril/Valsartan11$17,023
LinzessLinaclotide30$16,540
MyrbetriqMirabegron24$15,861
Atorvastatin Calcium857$14,054

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$120$123,644106 claims
AbbVieLinzess, Synthroid$118$20,55973 claims
AstraZenecaFarxiga$250$17,30617 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 159 primary care providers in Alabama.

Other primary care in Birmingham

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →